220114-01-2 Usage
Uses
Used in Chemical Synthesis Industry:
Dichloro(S)-(-)-2,2'-bis[di(3,5-xylyl)phosphino]-1,1'-binaphthyl[(2S)-(+)-1,1-bis(4-methoxyphenyl)-3-methyl-1,2-butanediamine]ruthenium(II) is used as a catalyst for the preparation of cyclometalated ruthenium 1,1-dianisyl-2-isopropyl-1,2-ethylenediamine complexes via asymmetric hydrogenation of ketones. This process is crucial for the synthesis of chiral compounds, which are essential in the pharmaceutical industry.
Used in Pharmaceutical Industry:
Dichloro(S)-(-)-2,2'-bis[di(3,5-xylyl)phosphino]-1,1'-binaphthyl[(2S)-(+)-1,1-bis(4-methoxyphenyl)-3-methyl-1,2-butanediamine]ruthenium(II) is used as a catalyst for enantioselective hydrogenation of an α-alkoxy substituted ketone with chiral ruthenium (phosphinoferrocenyl)oxazoline complexes. This application is significant for the production of enantiomerically pure pharmaceuticals, which are important due to their different biological activities.
Used in Organic Chemistry Research:
This ruthenium complex is also used for nonclassical asymmetric hydrogen transfer between alcohols and carbonyl compounds. This application is valuable for the development of new synthetic methods and the preparation of complex organic molecules.
Used in Asymmetric Hydrogenation:
Dichloro(S)-(-)-2,2'-bis[di(3,5-xylyl)phosphino]-1,1'-binaphthyl[(2S)-(+)-1,1-bis(4-methoxyphenyl)-3-methyl-1,2-butanediamine]ruthenium(II) is employed in the asymmetric hydrogenation of amino and heteroaromatic ketones. This process is essential for the synthesis of biologically active compounds and pharmaceutical intermediates.
Used in Cholesterol Absorption Inhibition:
In the pharmaceutical industry, Dichloro{(S)-(-)-2,2'-bis[di(3,5-xylyl)phosphino]-1,1'-binaphthyl}[(2S)-(+)-1,1-bis(4-methoxyphenyl)-3-methyl-1,2-butanediamine]ruthenium(II) is used as a catalyst for the synthesis of pharmacologically active substituted oxazolidinone, which acts as an NPC1L1 ligand for the inhibition of cholesterol absorption. This application is relevant for the development of drugs targeting hypercholesterolemia and related cardiovascular diseases.
Reaction
Highly active catalyst for hydrogenation of simple ketones giving high enantioselectivity when sterically unsymmetrical ketones such as acetophenone, heteroaryl ketones, benzophenones, cyclopropyl ketones, and cyclohexyl ketones are substrates. Ee's are enhanced with XylBINAP relative to BINAP. The otherwise poorly bonded ketone is held in the transition state by hydrogen bonding to the protic bidentate amine.
Carbonyl groups are selectively reduced even when olefins exist in the same molecule.
In the presence of strong base, and catalyst, simple ketones, having substituents at the α-position, may be induced to undergo dynamic kinectic resolution during their hydrogenation to produce two chiral carbon centers in high yield.
Check Digit Verification of cas no
The CAS Registry Mumber 220114-01-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,0,1,1 and 4 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 220114-01:
(8*2)+(7*2)+(6*0)+(5*1)+(4*1)+(3*4)+(2*0)+(1*1)=52
52 % 10 = 2
So 220114-01-2 is a valid CAS Registry Number.
220114-01-2Relevant articles and documents
RUTHENIUM COMPLEX AND METHOD FOR PREPARING OPTICALLY ACTIVE ALCOHOL COMPOUND
-
Page/Page column 24, (2011/11/13)
The present invention provides a novel ruthenium complex which has an excellent catalytic activity in terms of reactivity for asymmetric reduction of a carbonyl compound and enantioselectivity, a catalyst using the ruthenium complex, and a method for preparing optically active alcohol compounds using the ruthenium complex. The present invention relates to a ruthenium complex having ruthenacycle structure, a catalyst for asymmetric reduction consisting of the ruthenium complex, and a method for preparing optically active alcohol using the ruthenium complex.
